Elute Inc, a US-based developer of drug-eluting device technology for controlled and extended drug release, on Tuesday announced a strategic partnership with Spartan Medical Inc, a Service-Disabled Veteran-Owned and operated medical solutions company serving the Department of Veterans Affairs (VA), Department of Defense (DoD), civilian hospitals, and Ambulatory Surgery Centers (ASCs) nationwide.

This partnership will expand access to Elute's BonVie+ bone graft substitute to physicians and patients at VA and DoD medical facilities worldwide.

Bone graft substitutes are used to fill bone voids caused by trauma or infection. Traditional options such as bone cement and calcium sulphate-based granules can have significant drawbacks, Elute explained. Bone cement is non-biodegradable, does not support new bone growth, and often requires a second surgery for removal. Calcium sulphate substitutes resorb naturally but can cause fluid buildup (seromas) and wound drainage.

BonVie+ was developed to overcome these challenges. The implant gradually resorbs while being replaced by the patient's own healthy bone, creating a more natural and predictable path to healing.